FDA 483 - Johnson & Johnson Consumer Inc - August 12, 2010

An FDA inspection of Neutrogena Corporation in Los Angeles, CA, revealed a significant quality control deficiency. The firm failed to ensure that drug product production and control records were adequately reviewed by the quality control unit before batch release. Specifically, temperature excursions during mixing for Body Clear Body Wash lots were not identified during batch record review.